NasdaqGM:ACIUBiotechs
AC Immune (ACIU) Is Up 24.2% After Positive ACI-35.030 Trial Publication in Alzheimer's Disease
AC Immune SA recently announced the peer-reviewed publication of positive Phase 1b/2a trial results for its active immunotherapy ACI-35.030, in partnership with Janssen Pharmaceuticals, showing a rapid, robust, and durable immune response against pathological Tau proteins in early Alzheimer's disease.
The published data also highlighted that ACI-35.030 induced a sustained antibody response after the first injection in all patients, with no clinically relevant safety or tolerability issues...